Cerebral and spinal cord myxopapillary ependymomas: A case report

Moutaery, Khalaf Al; Aabed, M.; Ojeda, Victor J.

doi:10.1080/00313029600169394

Cited by 15 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The separate thoracic mass might have been detected had an MRI of the entire spine been obtained at initial diagnosis. In a 16-year-old male reported by Al Moutaery et al [23] who underwent a resection of a left temporal MPE, investigation of back pain 1 month after surgery revealed diffuse disease at the T12-L1 and L5-S1 levels. Their patient may have had metastases at initial presentation, which could have been detected by complete neuraxis evaluation.…”

Section: Discussionmentioning

confidence: 98%

Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation

Chinn

Donaldson

Dahl

et al. 2000

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation

Chinn

Donaldson

Dahl

et al. 2000

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

“…7 To date, there are 13 cases of pediatric myxopapillary ependymomas (MPE) with "anaplastic features" described in the literature. [12][13][14][15][16][17] Our study adds 5 additional cases with increased mitotic activity, 3 of which also demonstrated necrosis. Among the three patients with both increased mitotic activity and necrosis, two had disseminated disease and had disease recurrence.…”

mentioning

confidence: 74%

“…All cases showed chromosomal gains across the genome (Figure 3). The chromosomes with gains included 1, 2, 3,4,5,6,7,8,9,11,12,15,16,17,18,19,20,21,22, and X. Additional findings included copy neutral loss of heterozygosity of whole chromosome 8 includingMYC at 8q24.3 and copy neutral loss of heterozygosity on chromosome 13.…”

Section: Chromosomal Microarray Analysismentioning

confidence: 99%

“…]5 mitoses per 10 high-power fields). [12][13][14][15][16][17] However, there currently are no consensus criteria for classifying MPEs as histologically anaplastic and more importantly, clear treatment guidelines for this sub-group. Here, we present our institutional experience with pediatric MPEs, with detailed evaluation of their clinical and pathological features, and chromosomal microarray analysis, in order to help identify features associated with adverse outcomes among this patient population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pediatric Myxopapillary Ependymomas: Clinico-pathological Evaluation

Eschbacher¹,

Rao²,

Greipp³

et al. 2020

Preprint

View full text Add to dashboard Cite

PURPOSE: Myxopapillary ependymomas (MPE) have an indolent clinical course, corresponding to WHO Grade I designation. 13 pediatric MPEs have been reported in the literature to show "anaplastic features", including elevated proliferative activity ([?]5 mitoses per 10 high-power fields and/or Ki67 labeling index of >10%), necrosis, and microvascular proliferation. No consensus exists regarding the prognostic significance of such features. PROCEDURE: Retrospective clinicopathologic review of pediatric MPEs diagnosed between 1996-2018 at Mayo Clinic. RESULTS: The study included 8 pediatric MPEs (6 male; age range 7.52-16.88 years). 3 had disseminated disease at presentation. All patients underwent surgical resection (7 gross-total; 1 subtotal). 5 cases harbored [?]5 mitoses per 10 high-powered fields (range: 5-9), 3 of which showed necrosis (2 with disseminated disease). Following surgery, 2 patients received radiation; one with widely disseminated disease and another with increased mitotic activity and necrosis; neither has recurred at last follow-up (1.18 and 3.19 years). 2 patients with disseminated disease, elevated mitotic activity, and necrosis had new metastatic disease/progression of non-resected metastatic foci (2.6 and 26.8 months). Both received radiation therapy and have remained progression free (3.01 and 9.34 years). All patients are alive (median follow-up 1.31 years, range: 0.66-11.75 years). CONCLUSION: Our findings suggest that among pediatric MPEs, the concurrent presence of elevated mitotic activity and necrosis may be associated with a more aggressive clinical course, warranting closer surveillance and consideration of adjuvant therapies such as radiation. Attention to the presence of mitotic activity and necrosis may help identify children at higher risk for tumor recurrence/progression.

show abstract

“…Myxopapillary ependymomas tend to be WHO grade 1 and can be usually cured by resection when attached to the conus of filum terminiale. The intramedullary type are Grade II and therefore potentially more aggressive [ 16 , 17 ]. This case is unusual in that although it is at the level of the cauda equine it has the histological appearances of a classical intramedullary ependymoma rather than myxopapillary.…”

Section: Discussionmentioning

confidence: 99%